ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONCY Oncolytics Biotech Inc

1.44
0.03 (2.13%)
Dec 05 2023 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 159,731
Bid Price 1.37
Ask Price 1.51
News -
Day High 1.41

Low
1.09

52 Week Range

High
3.3942

Day Low 1.37
Company Name Stock Ticker Symbol Market Type
Oncolytics Biotech Inc ONCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.13% 1.44 19:52:18
Open Price Low Price High Price Close Price Prev Close
1.41 1.37 1.41 1.40 1.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
493 159,731 $ 1.39 $ 221,951 - 1.09 - 3.3942
Last Trade Time Type Quantity Stock Price Currency
19:47:05 formt 315 $ 1.44 USD

Oncolytics Biotech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
102.72M 73.37M - 0 -24.84M -0.34 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Oncolytics Biotech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ONCY Message Board. Create One! See More Posts on ONCY Message Board See More Message Board Posts

Historical ONCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.501.561.371.45413,862-0.06-4.0%
1 Month1.701.751.311.47469,081-0.26-15.29%
3 Months2.322.3451.311.74404,292-0.88-37.93%
6 Months1.693.39421.312.33785,304-0.25-14.79%
1 Year1.863.39421.092.17515,304-0.42-22.58%
3 Years4.134.830.80212.61535,717-2.69-65.13%
5 Years2.256.020.3512.48569,242-0.81-36.0%

Oncolytics Biotech Description

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The company's product pipeline includes Bavencio, Keytruda, Retifanlimab, and Tecentriq.

Your Recent History

Delayed Upgrade Clock